ReviewEye (London, England)2024
Neuro-ophthalmic evaluation and management of pituitary disease.
Review in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Bilateral visual failure with optic tract involvement in sellar-suprasellar lymphoma: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Persistent Rhinosinusitis-Like Symptoms Revealing a Lactotroph Pituitary Neuroendocrine Tumour: A Case Report.Cureus · 2026Article
- Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.Pituitary · 2026Article
- Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults - a retrospective, single institute experience.Journal of neuro-oncology · 2026Article
- Decoding visual pathway damage in pituitary macroadenomas: insights from retinal nerve fiber layer and visual field analysis.International ophthalmology · 2026Article
- Article
- Pituitary adenomas associated with hydrocephalus: clinical characteristics, risk stratification, and clinical management.Journal of neuro-oncology · 2026Article
- Clinical Features and Key Prognostic Indicators of Growth Hormone-Secreting Pituitary Adenomas: A Retrospective Study of 344 Cases.Current oncology (Toronto, Ont.) · 2026Article
- Prolactinoma-associated headache: Clinical and radiological correlates and long-term outcomes.Pituitary · 2026Article
- BDNF and TNF-α, OCT and VF Parameters in Pituitary Macroadenoma Patients: A 12-Month Prospective Study.International journal of molecular sciences · 2026Observational
- Neuroretinal damage associated with pituitary macroadenoma: endocrine and radiological predictors and correlation with optical coherence tomography-derived biomarkers.Frontiers in endocrinology · 2026Observational
- Investigating visual field measurements on perimetry and ganglion cell complex on optical coherence tomography in patients with suprasellar tumours.Journal of the colleges of medicine of South Africa · 2026Article
- Recovery in pupillometric non-visual functions following chiasmal decompression in pituitary adenoma.Brain communications · 2026Article
- Bridging engineering and neuro-oncology: a scalable FastAPI-deployed CNN framework for real-time explainable brain tumor diagnosis.Frontiers in neuroscience · 2026Article
- Non-human primates as preclinical models for optic nerve research: advancing insights into their application and potential.Eye (London, England) · 2025Review
- Optical coherence tomography and electroretinography in pituitary macroadenomas: a 12-month analysis by age and tumor type.Frontiers in endocrinology · 2025Observational
- A Real-World Longitudinal Study in Non-Functioning Pituitary Incidentalomas: A PRECES Micro-Adenomas Sub-Analysis.Diseases (Basel, Switzerland) · 2024Article
- Neuro-ophthalmology: recent advances and paradigm shifts.Eye (London, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuro-ophthalmic evaluation is a crucial component of the diagnostic and prognostic assessment of pituitary disease and compressive chiasmopathy, and can inform the timing of vision-restoring tumour resection surgery. The most common disease affecting the pituitary with neuro-ophthalmic implications are pituitary adenomas. Neuro-ophthalmic manifestations include decreased vision, abnormal colour vision and impaired visual field or diplopia. The recognition of these syndromes is critical to achieve early diagnosis and treatment and to improve prognosis. The pattern of vision loss in chiasmal compression is determined by the anatomical relationship between the pituitary lesion and optic chiasm, and potential visual field defects include bitemporal deficits, junctional scotomas, monocular cecocentral defects, and incongruous homonymous hemianopias. Rarer neuro-ophthalmic manifestations of pituitary disease include ophthalmoplegia, nystagmus, and obstructive hydrocephalus. There is growing evidence that demonstrates the strong diagnostic utility of optical coherence tomography (OCT) parameters in detecting the presence of compressive chiasmopathy, as well as the prognostic ability to predict the rate and degree of visual recovery following decompression surgery. Long-term neuro-ophthalmic monitoring is critical for detecting delayed vision loss following resection surgery, which may represent tumour recurrence or secondary complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.